Education
About Us
Working with TipRanks
Follow Us
Cadrenal Therapeutics, Inc. (CVKD)
:CVKD
CVKD Stock Chart & Stats
$12.92
-$1.27(-7.12%)
At close: 4:00 PM EST
$12.92
-$1.27(-7.12%)
Day’s Range― - ―
52-Week Range$8.74 - $22.90
Previous CloseN/A
Volume16.20K
Average Volume (3M)21.07K
Market Cap
$19.47M
Enterprise Value$24.41M
Total Cash (Recent Filing)$3.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 18, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding2,075,845
10 Day Avg. Volume19,850
30 Day Avg. Volume21,074
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.38
Price to Sales (P/S)0.00
P/FCF Ratio-2.40
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.12K
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$45.00Price Target Upside248.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-7.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThis is seen as a significant development for Cadrenal that advances a second tecarfarin indication to clinical trials.
Efficacy And Patient OutcomesTecarfarin has shown improvements in efficacy and the ability to maintain the patient within their target blood clotting ranges, potentially reducing hospitalization rates, morbidity, and mortality.
PartnershipsCadrenal announced a development agreement with Abbott to develop Tecarfarin in patients with Abbott’s HeartMate3 LVAD.
Bears Say
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $8.74 and its highest was $22.90 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $19.47M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 109 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on Nov 10, 2025. The company reported -$1.31 earnings per share for the quarter, beating the consensus estimate of -$1.55 by $0.24.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.21.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 2,075,845 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.31 in its last earnings report, beating expectations of -$1.55. Following the earnings report the stock price went down -3.13%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$45.00
▲(248.30% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
51.58% Insiders
2.87% Mutual Funds
<0.01% Other Institutional Investors
43.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---